Overview

A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
To compare R-CHOP plus enzastaurin versus R-CHOP for progression-free survival (PFS) time measured in participants with intermediate and/or high risk for diffuse large B-cell lymphoma (DLBCL) receiving first-line treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cyclophosphamide
Doxorubicin
Prednisone
Rituximab
Vincristine